Co-infection of COVID-19 patients with atypical bacteria: A study based in Jordan.

Autor:	Alsayed AR; Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Applied Science Private University, Amman 11931-166, Jordan. a_alsayed@asu.edu.jo, a.alsayed.phd@gmail.com., Hasoun L; Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Applied Science Private University, Amman 11931-166, Jordan. l_hason@asu.edu.jo., Khader HA; Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, PO Box 330127, Zarqa 13133, Jordan. hebaa@hu.edu.jo., Abu-Samak MS; Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Applied Science Private University, Amman 11931-166, Jordan. m_abusamak@asu.edu.jo., Al-Shdifat LM; Department of Pharmaceutical Chemistry and Pharmacognosy, Faculty of Pharmacy, Applied Science Private University, Amman 11931-166, Jordan. l_alshdifat@asu.edu.jo., Al-Shammari B; Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Applied Science Private University, Amman 11931-166, Jordan. bashir99ali@gmail.com., Maqbali MA; Department of Nursing Midwifery and Health, Northumbria University, Newcastle-Upon-Tyne, UK. mohammed.maqbali@northumbria.ac.uk.
Jazyk:	angličtina
Zdroj:	Pharmacy practice [Pharm Pract (Granada)] 2023 Jan-Mar; Vol. 21 (1), pp. 2753. Date of Electronic Publication: 2022 Nov 09.
DOI:	10.18549/PharmPract.2023.1.2753
Abstrakt:	Objective: The aim of this work was to know the prevalence of Chlamydophila pneumoniae and Mycoplasma pneumoniae in coronavirus disease 2019 (COVID-19) patients in Jordan. Also, to assess a TaqMan real-time polymerase chain reaction (PCR) assay in detecting these two bacteria. Methods: This is a retrospective study performed over the last five months of the 2021. All nasopharyngeal specimens from COVID-19 patients were tested for C. pneumonia, and M. pneumoniae. The C. pneumoniae Pst-1 gene and M. pneumoniae P1 cytadhesin protein gene were the targets. Results: In this study, 14 out of 175 individuals with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (8.0%) were co-infected with C. pneumoniae or M. pneumoniae . Co-infection with SARS-CoV-2 and C. pneumoniae was reported in 5 (2.9%) patients, while 9 (5.1%) patients had M. pneumoniae and SARS-CoV-2 co-infection. The mean (± std) of the correlation coefficient of the calibration curve for real-time PCR analysis was -0.993 (± 0.001) for C. pneumoniae and -0.994 (± 0.003) for M. pneumoniae . The mean amplification efficiencies of C. pneumoniae and M. Pneumoniae were 187.62% and 136.86%, respectively. Conclusion: In this first study based in Jordan, patients infected with COVID-19 have a low rate of atypical bacterial co-infection. However, clinicians should suspect co-infections with both common and uncommon bacteria in COVID-19 patients. Large prospective investigations are needed to give additional insight on the true prevalence of these co-infections and their impact on the clinical course of COVID-19 patients. (Copyright: © Pharmacy Practice.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu